9. (Previously Presented) The method of claim 8, wherein the allergy is asthma.

10. (Previously Presented) The method of claim 5, whereby IgG-induced phagocytosis is inhibited.

11. (Previously Presented) The method of claim 10, whereby IgE-mediated exocytosis is further inhibited.

12. (Previously Presented) The method of claim 9, whereby antigen-induced bronchial hyper reactivity is prevented.

13. (Previously Presented) The method of claim 5, wherein the monovalent antibody fragments are administered in a form of a composition.

14. (Previously Presented) The method of claim 13, wherein the composition is administered by injection.

15. (Previously Presented) The method of claim 14, wherein the injection is intramuscular, intradermal, intravenous, intraperitoneal or subcutaneous.

16. (Previously Presented) The method of claim 13, wherein the composition is administered by aerosol.

17. (Previously Presented) The method of claim 5, wherein the mammal is human.

18. (Previously Presented) The method of claim 5, wherein the antibody fragments are Fab fragments of an anti-FcαRI mAb.

19. (Previously Presented) The method of claim 18, wherein the anti- FcαRI mAb is (IgGlk, clone A 77).

20. (Previously Presented) A pharmaceutical composition, comprising:

a) monovalent antibody fragments directed against mammalian

FcαRI receptor, and

b) a carrier.

21. (Previously Presented) The pharmaceutical composition of claim 20, in a form suitable for injection.

22. (Previously Presented) The pharmaceutical composition of claim 20, in a form suitable for inhalation.

23. (Previously Presented) The pharmaceutical composition of claim 20, wherein the monovalent antibody fragments are directed against EC2 domain of the FcαR1 receptor.

24. (Previously Presented) The pharmaceutical composition of claim 20, wherein the antibody fragments of an anti- FcαRI mAb.

25. (Previously Presented) The pharmaceutical composition of claim 24, wherein the anti-FcαRI mAb is (IgGlk, clone A 77).